Dasatinib

Catalog No.S1021

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Dasatinib Chemical Structure

Dasatinib Chemical Structure
Molecular Weight: 488.01

Validation & Quality Control

Cited by 62 publications:

10 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Src Inhibitors with Unique Features

  • Pan Src Inhibitor

    Saracatinib (AZD0530) Pan-Src inhibitor, IC50=2.7-11 nM for c-Src/c-Yes/Fyn/Lyn/Blk/Fgr/Lck.

  • FDA-approved Src Inhibitor

    Bosutinib (SKI-606) Approved by FDA for Ph+ chronic myelogenous leukemia (CML).

  • Newest Src Inhibitor

    PP1 Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • Classic Src Inhibitor

    KX2-391 The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Product Information

  • Compare Src Inhibitors
    Compare Src Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
IC50 0.6 nM 0.8 nM 37 nM 79 nM
In vitro Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
M07ep210NV7jdY9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXi4eXRPPzJiaB?=MoCySG1UVw>?M1\BeGlEPTB;MD6wNFAxPyEQvF2=NF;oO|AyPzl3NkC4NC=>
K562Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWe3NkBpMW\EUXNQM133TWlEPTB;MD6wNFEh|ryPMlPYNVc6PTZyOEC=
M07eNYTEdWVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXXbnhjPzJiaB?=Ml[1SG1UVw>?MoLFTWM2OD1yLkCwNVIh|ryPMYixO|k2PjB6MB?=
ALL3NI\L[mdEgXSxdH;4bYMhSXO|YYm=NIr5TJExNjIQvF2=NUL5UYo3PzJiaB?=M{fEcGROW09?MWHJR|UxRTBwMECwOEDPxE1?MVqxPVg5QTV2MB?=
CMLNWn6NVFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\5SHVNOjBibXnuMULEUXNQNHrKcZpKSzVyPUCuNFAyKM7:TR?=MYexPVIyQTBzNh?=
BA/F3MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXG3NkBpNUP6R3hOTE2VTx?=MkjKTWM2OD14LkW4PUDPxE1?M{DGNlI{ODh6NkS0
BA/F3MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{Gx[VczKGh?MlHZSG1UVw>?MnrsTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDNN|UyXCCvdYThcpQhf2m2aDDJR|UxKG:oIECuNFAxQDQQvF2=MUSyN|A5QDZ2NB?=
BA/F3NGfuNHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rLSlczKGh?M4rmbWROW09?MoruTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3Orbnege4lt\CC2eYDlJGJkei2DYnyge4l1cCCLQ{WwJI9nKDBwMEC0Oe69VQ>?NV7hcYxkOjNyOEi2OFQ>
BA/F3MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXm3NkBpNF\UbW1FVVORNX7vbnNEUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBVOzF3STDteZRidnRid3n0bEBKSzVyIH;mJFEvPzF2zszNNWLFZldwOjNyOEi2OFQ>
BA/F3MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\PO|IhcA>?MUPEUXNQMXTJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBHPDh4UzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECwPe69VQ>?M2H0S|I{OzBzN{Cz
BA/F3NHqyfFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzkO|IhcA>?NHnUOIdFVVORMmr5TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTJ3NVugcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwN|LPxE1?NXLkV2tHOjN|MEG3NFM>
BA/F3NVPvXmVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV63NkBpMYDEUXNQMmfLTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTzJ3MFWgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwOVHPxE1?NFnGO5gzOzNyMUewNy=>
BA/F3MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPWSYg4OiCqNUHUe3pyTE2VTx?=M3nQSGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFF{NULIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFjPxE1?MVWyN|MxOTdyMx?=
BA/F3MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLJWHc4OiCqNY\iPG5ITE2VTx?=MlHHTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTN3OW[gcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVPPxE1?MVSyN|MxOTdyMx?=
BA/F3MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojOO|IhcA>?M3nsW2ROW09?NVPCNGhPUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDCR3IuSUKOIHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVnPxE1?M3:3WVI{OzBzN{Cz
BA/F3MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4fNNVczKGh?NEXvVIlFVVORNEPGWJRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCC\MkWzTEBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAzO87:TR?=MU[yN|MxOTdyMx?=
BA/F3M1\US2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LEfFczKGh?NVzSXnFYTE2VTx?=NUT0d2YzUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiVEOxOWkhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCzMlbPxE1?NY\YeoRTOjN|MEG3NFM>
BA/F3M3:yT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPBO|IhcA>?NVrabHk1TE2VTx?=NF\weZZKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAzNjYQvF2=MY[yN|MxOTdyMx?=
T cellMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnW3O|IhcA>?NYL0cpd3TE2VTx?=MnfZTY5pcWKrdIOgZY51cSCFREOtJIFv\CCjboTpJGNFOjhvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEROwG0>NFT5T2syPzF3NEWxNi=>
WiDrM{LZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTPSphsPzJiaB?=M3XLPGROW09?M{TEeWlEPTB;MD6wOVIh|ryPNYqwNWFUOTV4MUW1NVI>
PC3MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLYO|IhcA>?MUHEUXNQM3nB[mlEPTB;MD6wNFk1KM7:TR?=MkHQNVU3OTV3MUK=
MDA-MB-231M1PQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\QTYk4OiCqNFnNSXNFVVORM4riPGlEPTB;MD6wNVIh|ryPMofkNVU3OTV3MUK=
Hs578TNYnPcHFtS3m2b4TvfIlkKEG|c3H5MWW3NkBpM17ZN2ROW09?NUOyNolmT0l3ME2wMlA{KM7:TR?=NYfQUWJWOjRyMUWzNlc>
HMECMofUR5l1d3SxeHnjJGF{e2G7MWW3NkBpMmH3SG1UVw>?NFfYVXpIUTVyPUGuPEDPxE1?M2rsV|I1ODF3M{K3
DU145MnnMR5l1d3SxeHnjJGF{e2G7M2LXU|czKGh?NFzhWm1FVVORMoXoS2k2OD1yLkG2JO69VQ>?NWPiZnM5OjRyMUWzNlc>
U251M2TqO2N6fG:2b4jpZ{BCe3OjeR?=MVm3NkBpMnjhSG1UVw>?M3Tve2dKPTB;Mj64NUDPxE1?MY[yOFAyPTN{Nx?=
NCI60M{n5dWN6fG:2b4jpZ{BCe3OjeR?=NWTBRlJHPzJiaB?=NFLPXI1FVVORMnjSS2k2OD13Lkeg{txONU\MV4g2OjRyMUWzNlc>
MALME-3MNHLYe4NEgXSxdH;4bYMhSXO|YYm=NXHJW4E5PzJiaB?=M4\QVGROW09?MoXBS2k2OD14Lk[xJO69VQ>?MmnVNlQxOTV|Mke=
KM12M3r5[mN6fG:2b4jpZ{BCe3OjeR?=NW\VWHRJPzJiaB?=NW\T[WtGTE2VTx?=NXvqe2FsT0l3ME23MlQ1KM7:TR?=NVjWPY1pOjRyMUWzNlc>
SW620NEnlVWpEgXSxdH;4bYMhSXO|YYm=NGfjVWQ4OiCqMUHEUXNQNG[4[2JIUTVyPUiuOFMh|ryPMlXWNlQxOTV|Mke=
RXF 393NLMn64R5l1d3SxeHnjJGF{e2G7MUG0JIRigXN?NXTqTI0{TE2VTx?=MYrJR|UxRTBwMEKxO{DPxE1?NILZc2IzOzJ3M{C3OC=>
LXFA 983LM2DRbmN6fG:2b4jpZ{BCe3OjeR?=Mk\EOEBl[Xm|NYjXNmJpTE2VTx?=M3z2SWlEPTB;MD6wOVY2KM7:TR?=Mn:3NlMzPTNyN{S=
PRXF DU145M3r2OGN6fG:2b4jpZ{BCe3OjeR?=M1jaSVQh\GG7cx?=M1\IdmROW09?NG\tOotKSzVyPUCuNFYzOyEQvF2=MkLpNlMzPTNyN{S=
PAXF 1657LM4fDNWN6fG:2b4jpZ{BCe3OjeR?=Mlq4OEBl[Xm|NH7WdZVFVVORMnz1TWM2OD1yLkGyNUDPxE1?MUGyN|I2OzB5NB?=
CXF 1103LNWO2SG57S3m2b4TvfIlkKEG|c3H5MYG0JIRigXN?NHLvOJJFVVORMnjBTWM2OD12LkO2JO69VQ>?M1LDdlI{OjV|MEe0
GXF251LMn\pR5l1d3SxeHnjJGF{e2G7Ml;6OEBl[Xm|Ml7NSG1UVw>?NX7DTpB2UUN3ME2yMlI2KM7:TR?=MlrkNlMzPTNyN{S=
NCI-H23MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVK3NkBpM{PRTmROW09?M2XNPGlEPTB;Mj6yO{DPxE1?MYmyN|UzOTB{MB?=
HCT116MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnOO|Q4PzJiaB?=M3y0bGROW09?MYnJR|UxRTJwMzFOwG0>M1flUVI{PTJzMEKw
MCF7MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXRbJY4OiCqMo[4SG1UVw>?MlPSTWM2OD1{LkW3JO69VQ>?M1PSTlI{PTJzMEKw
NCI-H460MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUG3NkBpMUPEUXNQNHn6VIVKSzVyPUiuPVkh|ryPNHfrOoczOzV{MUCyNC=>
DLD1Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PPWVczKGh?MnW0SG1UVw>?M161S2lEPTB;ND62JO69VQ>?MkLtNlM2Pjd7NkC=
NCI-H661M1vzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlv6O|IhcA>?MWrEUXNQMXfJR|UxRTdwODFOwG0>M33JdVI{PTZ5OU[w
A549MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVO3NkBpNEPKb|dFVVORNFrYU2VKSzVyPUiuNkDPxE1?MU[yN|U3Pzl4MB?=
U937NYPaPGN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfQO|IhcA>?MnmySG1UVw>?M{LLbWlEPTB;MUKuNkDPxE1?NUHXWplnOjN3Nke5OlA>
HEK293M2HmSmZ2dmO2aX;uJGF{e2G7M4C0R|ExyqEQvF2=NXXVZnRFTE2VTx?=MkTCTY5lfWOnczDibY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIH\1cIwudGWwZ4ToJGhqey22YXfn[YQhVXm2MTDrbY5ie2ViZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC5aYToJGlEPTBib3[gNE4xPjQQvF2=MmX4NlI4PzB4MUC=
HUVECNHjaXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzh[pcxNjF3wrFOwG0>NXe3NIM6PzJiaB?=MkjYSG1UVw>?NGf1O25KdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0>M1q2OVIzQDV|OUmz
HUVECMkT2SpVv[3Srb36gRZN{[Xl?NYnSTWp6OTYEoN88US=>NXfi[GdYPzJiaB?=NIC5NWlFVVORM{TGWGlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVOM4DV[|IzQDV|OUmz
Plasmodium falciparumMoTYSpVv[3Srb36gRZN{[Xl?NYjQ[GxQOTEEoN88US=>MWSxOUBucW5?NVTUXm5MTE2VTx?=MYnJcohq[mm2czDQcIF{dW:maYXtJIZidGOrcHHyeY0heHKxbHnm[ZJifGmxbjDifUBqdmirYnn0bY5oKHSqZTDGeY5kfGmxbjDv[kBR\kOGUFuxJJBzd3SnaX6ge4l1cCCLQ{WwJI9nKDFwMUhOwG0>NYHnUJN2OjR3NUCzN|A>
PC3M4jKNmZ2dmO2aX;uJGF{e2G7NUi0bVhoOC5zIN88US=>M2\hTVUhcA>?MY\EUXNQMVPJcohq[mm2czDoeY1idiCSQ{OgZ4VtdCCjZHjld4lwdiCjdDCxNFAhdk1?MlnKNVk1PjJ7N{W=
DU145NHjWUnlHfW6ldHnvckBCe3OjeR?=MnHUNE4yKM7:TR?=MoTDOUBpMXjEUXNQMUfJcohq[mm2czDoeY1idiCGVUG0OUBk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?=M3TwcFE6PDZ{OUe1
PC3NVrjbGxlU2mwYYPlJGF{e2G7Mk\DNE4yKM7:TR?=NUjyWnlQPSCqNYXxUlB3TE2VTx?=MXfJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgV5JkKFl2MU[gcIV3\WxiYYSgNVAxKG6PM1zhZVE6PDZ{OUe1
DU145NG\hfVZMcW6jc3WgRZN{[Xl?NYjHNo9xOC5zIN88US=>M1HWSVUhcA>?NV70RnkzTE2VTx?=NYf2No1qUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiU4LjJHk1OTZibHX2[Ywh[XRiMUCwJI5OM3PvN|E6PDZ{OUe1
PC3NEXhbWNMcW6jc3WgRZN{[Xl?NGHmRVMxNjFizszNNWjtUpNlPSCqNITZT2hFVVORNGTJT|RKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1?M3TsVlE6PDZ{OUe1
DU145NVK4PFRsU2mwYYPlJGF{e2G7M3HJdVAvOSEQvF2=NUfJc2l[PSCqNGezWFJFVVORMoTXTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1?MWqxPVQ3Ojl5NR?=
Huh7MnvCRY51cX[rcnHsJGF{e2G7M3PzRlIvPSEQvF2=NHTiPG01KGSjeYO=M3HrbGROW09?MnfLTY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBpfW2jbjDIeYg4KGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWPNWj1PXM3OTd|NkC2O|Y>
C6/36MVnBcpRqfmm{YXygRZN{[Xl?NG\1e|QzNjVizszNMl6wOEBl[Xm|NXv1cY5vTE2VTx?=MnH4TY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBie2mjbjD0bYdmeiCvb4PxeYl1dyCFNj:zOkBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[geolz[WxiZX72[YxweGVicILveIVqdiC5aYTobY4heGW{aX71Z4xm[XJicnXnbY9vKGG2IEKuOUB2VQ>?MUOxO|M3ODZ5Nh?=
U937M3HyW2Z2dmO2aX;uJGF{e2G7MUCxJO69VQ>?M1PvN|EhcA>?MYfEUXNQNWP3T5JVWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO=NHHQblcyPzZ6NEC5PS=>
U937NGjZfHRHfW6ldHnvckBCe3OjeR?=NGXGdY0yKM7:TR?=Ml\VNUBpMXzEUXNQNX\FWplIWmWmdXPld{BNWFNvaX7keYNm\CCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN?NFntRpUyPzZ6NEC5PS=>
murine mast cellMWnGeY5kfGmxbjDBd5NigQ>?M3ezUFEh|ryPMoCwNlQhcA>?Mk[zSG1UVw>?Mn\mTY5pcWKrdIOgZY51cWenbj3pcoR2[2WmIFnMOkB{\WO{ZYTpc44hcW5iSXfFJJBzcW2nZDDtc5V{\SCvYYP0JINmdGy|IHH0JFEhfU1?NUO0[GFSOTd4OESwPVk>
BV-173NUXVWFJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHoTWM2OD1yLkCwNFAxODFyOTFOwG0>MmSyV2FPT0WU
K-562NFPKWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\rVoN3UUN3ME2wMlAxODByMEK2OkDPxE1?M1jy[HNCVkeHUh?=
BL-70NGXsbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2HaSGlEPTB;MD6wNFAxODB6MkKg{txOMWTTRW5ITVJ?
EM-2MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7TNIlvUUN3ME2wMlAxODByMUC4JO69VQ>?NH;tXo1USU6JRWK=
LAMA-84MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoP6TWM2OD1yLkCwNFAxOzJzIN88US=>NInmWWVUSU6JRWK=
MEG-01NE\pPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETTR4NKSzVyPUCuNFAxODB7ODFOwG0>NH7EbYxUSU6JRWK=
EoL-1-cellNWjHS|huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfUdoVDUUN3ME2wMlAxODBzM{Gg{txONFS1OmFUSU6JRWK=
CTV-1MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHieJh3UUN3ME2wMlAxODB2MESg{txONXP6UIxLW0GQR1XS
TE-15NYXZcodWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFu1bo1KSzVyPUCuNFA2QDlizszNMn7iV2FPT0WU
NOS-1M2\hb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\hUGlEPTB;MD6wNFYyOyEQvF2=NWntdWFDW0GQR1XS
D-336MGMnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTBwMEC2N{DPxE1?Mnz4V2FPT0WU
LB1047-RCCMnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkC4TWM2OD1yLkCwPVg6KM7:TR?=MYPTRW5ITVJ?
LB996-RCCNG\lNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTBwMEC5PVEh|ryPMkDYV2FPT0WU
SW982M4TzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\yTWM2OD1yLkCxNVE2KM7:TR?=NHXlXllUSU6JRWK=
TK10NIHYOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTBwMEGxO|Qh|ryPMlXDV2FPT0WU
A704MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFuySFVKSzVyPUCuNFE1QTFizszNMYPTRW5ITVJ?
TE-8MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTUTWM2OD1yLkCxOVc3KM7:TR?=M3nqNXNCVkeHUh?=
DOHH-2NUexbpY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\nNWlEPTB;MD6wNVcyQSEQvF2=MkDrV2FPT0WU
HOP-62NYfwbG93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojzTWM2OD1yLkCxPFM1KM7:TR?=MV\TRW5ITVJ?
TE-12M4fRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\hTWM2OD1yLkCxPFYyKM7:TR?=M4f5NnNCVkeHUh?=
KGNMkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFqwdmdKSzVyPUCuNFE6PDJizszNMl;tV2FPT0WU
NCI-H1648NUXIepZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLxTYlNUUN3ME2wMlAzODFzIN88US=>NH;OOo9USU6JRWK=
OS-RC-2NGHlN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF7LW|RKSzVyPUCuNFIxOyEQvF2=M3X4OHNCVkeHUh?=
GB-1M3\l[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn:wTWM2OD1yLkCyNVU4KM7:TR?=NH\lNWRUSU6JRWK=
RXF393MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LSNmlEPTB;MD6wNlM2PyEQvF2=NVXtdYliW0GQR1XS
LC-2-adM3PDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{mxN2lEPTB;MD6wNlU5PiEQvF2=NVLEeI5iW0GQR1XS
KS-1MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITOO|lKSzVyPUCuNFI4OyEQvF2=MYXTRW5ITVJ?
ETK-1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPSV3BjUUN3ME2wMlAzQDN{IN88US=>NVS4c2JuW0GQR1XS
SW954MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDTTWM2OD1yLkCyPVI4KM7:TR?=M3ruNHNCVkeHUh?=
BeckerM{HycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYroSVdHUUN3ME2wMlA{ODB|IN88US=>NXPmNlFWW0GQR1XS
MZ1-PCMofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTsbI9KSzVyPUCuNFMyOTlizszNM3rnWnNCVkeHUh?=
ES6NGH2e2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnXTWM2OD1yLkCzNVk{KM7:TR?=M4rzSXNCVkeHUh?=
KURAMOCHIM{TBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjZcoVKSzVyPUCuNFM1QDdizszNM1LLb3NCVkeHUh?=
CGTH-W-1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTBwMEO1OFgh|ryPMn3pV2FPT0WU
VA-ES-BJMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrLRlVKSzVyPUCuNFM6ODJizszNMn;4V2FPT0WU
LXF-289NWDQeFJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTBwMEO5OVYh|ryPM{LqNXNCVkeHUh?=
MPP-89NXThc3g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;WdGlEPTB;MD6wOFA1QSEQvF2=M{\Fd3NCVkeHUh?=
SW872M{HRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVf0Xmh2UUN3ME2wMlA1OTZzIN88US=>MlnQV2FPT0WU
SNB75MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTBwMES0N|Uh|ryPMYXTRW5ITVJ?
PSN1NH;SZ|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\XelFKSzVyPUCuNFQ1PzRizszNNFzaUWFUSU6JRWK=
LB831-BLCNFvhSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljtTWM2OD1yLkC0OlA6KM7:TR?=NVXROHk1W0GQR1XS
MFH-inoMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTBwMES3NlQh|ryPMWjTRW5ITVJ?
TGBC24TKBMnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MniwTWM2OD1yLkC0O|YyKM7:TR?=MVvTRW5ITVJ?
A388NEnCUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfFc5c2UUN3ME2wMlA2ODl3IN88US=>MkniV2FPT0WU
BB30-HNCMn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETCOJFKSzVyPUCuNFU1OzdizszNNVrINpNUW0GQR1XS
GI-ME-NMnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M173[mlEPTB;MD6wOlEyQCEQvF2=MoDmV2FPT0WU
TGBC1TKBM3LqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4f3emlEPTB;MD6wOlE3PCEQvF2=M4LBNHNCVkeHUh?=
TE-10MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7JTHV5UUN3ME2wMlA3OzV5IN88US=>NFXaNmxUSU6JRWK=
A498MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\LNYU6UUN3ME2wMlA4Ojh2IN88US=>MUPTRW5ITVJ?
TE-11M3zOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTBwMEe4OVgh|ryPMlXGV2FPT0WU
BB65-RCCNHe2NpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml24TWM2OD1yLkC4NlI4KM7:TR?=MVvTRW5ITVJ?
C2BBe1MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnHTWM2OD1yLkC4N|A5KM7:TR?=NUnwSmNQW0GQR1XS
NCI-H747MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTBwMEizOlIh|ryPNUj3R3N5W0GQR1XS
IST-MES1NF3sSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInYZW5KSzVyPUCuNFg2PTJizszNMoL5V2FPT0WU
KALS-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7wTWM2OD1yLkC5OFkh|ryPNXK3dHh{W0GQR1XS
GCIYNXvkSo0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTmTWM2OD1yLkC5OlU3KM7:TR?=M{XjNXNCVkeHUh?=
RL95-2MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1f2TWlEPTB;MD6xNFM5KM7:TR?=NID1[ndUSU6JRWK=
TE-1MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTBwMUC1OEDPxE1?MXHTRW5ITVJ?
NCI-H1355NHLYUGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2r4bmlEPTB;MD6xNVAzQCEQvF2=MU\TRW5ITVJ?
SW962NFHPV|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTBwMUGyPVIh|ryPMmTaV2FPT0WU
KLENWDObVBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLFbW43UUN3ME2wMlEyOzF5IN88US=>MUTTRW5ITVJ?
MC116NWfDZ|d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPFVo1qUUN3ME2wMlEyPDFizszNMoDrV2FPT0WU
NMC-G1NU\HW452T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7GfpJKSzVyPUCuNVE3ODZizszNMW\TRW5ITVJ?
KU812NI\YUoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkPtTWM2OD1yLkGxPFg{KM7:TR?=NXTaWXZuW0GQR1XS
COLO-829NF\4UI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTVfZlbUUN3ME2wMlEzOjF|IN88US=>NHrTTHNUSU6JRWK=
NTERA-S-cl-D1MnvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXuVI1KSzVyPUCuNVIzQDNizszNM2nmT3NCVkeHUh?=
IST-MEL1M1XFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELNcYFKSzVyPUCuNVM1PSEQvF2=MnzkV2FPT0WU
MLMAM4fK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;5XndrUUN3ME2wMlE1ODN{IN88US=>MWDTRW5ITVJ?
LS-123NETCepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTBwMUSwOlQh|ryPMoL2V2FPT0WU
LB2518-MELNGW3TWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTBwMUSxOlIh|ryPNILZO45USU6JRWK=
NB69NXy0NFU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTBwMUS0N|Yh|ryPNH3m[FZUSU6JRWK=
8-MG-BAM2rsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3Wzc2lEPTB;MD6xOVQ2QCEQvF2=NIXRcJNUSU6JRWK=
K5MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIPGcZdKSzVyPUCuNVY1QDlizszNMnTIV2FPT0WU
KINGS-1M1;WZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXaUXhvUUN3ME2wMlE3PjZ4IN88US=>NU\keGZxW0GQR1XS
SF268M{X2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHL2dZFKSzVyPUCuNVc1ODRizszNMnrHV2FPT0WU
PF-382NHLtZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLkTYxKSzVyPUCuNVc3PzhizszNM1PMenNCVkeHUh?=
SH-4M{fGVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTW[FBpUUN3ME2wMlE5PDF|IN88US=>NYPKO4lsW0GQR1XS
NALM-6M{H2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV[0SZpbUUN3ME2wMlE6Ojl3IN88US=>NULEU5c1W0GQR1XS
CP66-MELMnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjPTWM2OD1yLkG5OVMyKM7:TR?=M{\DOnNCVkeHUh?=
697MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2K3V2lEPTB;MD6xPVk5PyEQvF2=M{TPeXNCVkeHUh?=
CP67-MELM{XuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWm3U484UUN3ME2wMlIxPDh6IN88US=>NICzbWtUSU6JRWK=
DSH1MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{T1emlEPTB;MD6yOFAxOSEQvF2=MUXTRW5ITVJ?
HCE-4NWH3[plnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7xXVJKSzVyPUCuNlY1OzlizszNNXuwO4dYW0GQR1XS
MZ2-MELM37l[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXz[YhKSzVyPUCuNlg2OzdizszNMknkV2FPT0WU
BL-41NWLr[G9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\kTWlEPTB;MD6yPVEzOyEQvF2=M2DnNXNCVkeHUh?=
HUTU-80NYfaXVVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjqXWhoUUN3ME2wMlMyPDJizszNM1HaXXNCVkeHUh?=
LOXIMVIMmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlj1TWM2OD1yLkOxOVA{KM7:TR?=M3rJd3NCVkeHUh?=
no-10MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4WyNmlEPTB;MD6zNVk{OSEQvF2=MmPTV2FPT0WU
KARPAS-422NXzndol6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX71dFJxUUN3ME2wMlM{QTl5IN88US=>MnzXV2FPT0WU
SW684MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfEZlhKSzVyPUCuN|Q6QCEQvF2=NHPBPZFUSU6JRWK=
SF126MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPlWXZYUUN3ME2wMlM2PDFizszNNFrvVnJUSU6JRWK=
D-263MGMmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTBwM{[yNlQh|ryPMkftV2FPT0WU
OVCAR-4M2fBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV23fJh5UUN3ME2wMlM4PDN|IN88US=>M1PpS3NCVkeHUh?=
BB49-HNCNIDrOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTBwM{i1PVkh|ryPNHXHOY9USU6JRWK=
ONS-76MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTBwNEK5OVEh|ryPNHnEdZRUSU6JRWK=
MZ7-melNXj5VW5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXj0cndtUUN3ME2wMlQ4QTFzIN88US=>M1v5XHNCVkeHUh?=
RCC10RGBNXzCOFVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\vfolKSzVyPUCuOFkyOSEQvF2=Ml7iV2FPT0WU
BOKUM1\kUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4X0eGlEPTB;MD60PVE{OyEQvF2=NFrpUZRUSU6JRWK=
no-11NX36NJNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4Kw[WlEPTB;MD61NFIzQCEQvF2=MUnTRW5ITVJ?
IST-SL2M1LMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX[zXo0{UUN3ME2wMlUxOzB{IN88US=>NWLzRXI{W0GQR1XS
RKOMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\2TWM2OD1yLkWyPVY3KM7:TR?=M3nEWnNCVkeHUh?=
HT-144MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTBwNUO2NFkh|ryPNFjEZlhUSU6JRWK=
NCI-H446MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTBwNkK3OkDPxE1?MojWV2FPT0WU
QIMR-WILNEO4TXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nLc2lEPTB;MD63NFYzQSEQvF2=M2jqV3NCVkeHUh?=
MHH-PREB-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnP2TWM2OD1yLke0OFY6KM7:TR?=MnLNV2FPT0WU
EW-16M2TuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHL[2E4UUN3ME2wMlc3OTd6IN88US=>NGPZ[ZhUSU6JRWK=
EW-24NVvVNoI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2fudGlEPTB;MD63PFE3PSEQvF2=MWLTRW5ITVJ?
LB373-MEL-DNGq4dHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TUO2lEPTB;MD64NlUxQCEQvF2=NHfZdGZUSU6JRWK=
TE-9MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTYdZZCUUN3ME2wMlg4PTN{IN88US=>NVrJZYNrW0GQR1XS
A3-KAWMmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTBwOUi0OVIh|ryPMWfTRW5ITVJ?
A101DMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIPOXnhKSzVyPUGuNFMxPDNizszNNHP6O5NUSU6JRWK=
OCUB-MNV3nSY1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3K1eWlEPTB;MT6wOFQyOiEQvF2=MUPTRW5ITVJ?
ES4MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTFwMEWxOFUh|ryPM4jOWHNCVkeHUh?=
TE-6MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnPTWM2OD1zLkKxNlI3KM7:TR?=MXXTRW5ITVJ?
D-502MGNXrhVZJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2ftSWlEPTB;MT6yN|M4PiEQvF2=NFzpWFdUSU6JRWK=
KNS-42NIDoZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7KTWM2OD1zLkK0OFEzKM7:TR?=NFm3WoNUSU6JRWK=
SNU-C2BNHPLTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLTTZJ7UUN3ME2xMlMxPTh7IN88US=>NIPnRndUSU6JRWK=
NCI-H1838MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTFwM{C3N|Mh|ryPMonSV2FPT0WU
NKM-1M2q5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTFwM{C4OVkh|ryPNWLnc|BwW0GQR1XS
GI-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LaTGlEPTB;MT6zOlIzKM7:TR?=NFf3OXdUSU6JRWK=
NB5M3HZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXLZ3I5UUN3ME2xMlM6QDJ5IN88US=>NH3RWYNUSU6JRWK=
CAS-1MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTFwNEC5PVIh|ryPMmDoV2FPT0WU
HCE-TMoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33HZ2lEPTB;MT61OlcyPCEQvF2=NHPycllUSU6JRWK=
SBC-1Mmm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;vVppKSzVyPUGuOVc6QDRizszNMXLTRW5ITVJ?
JiyoyeP-2003MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHBTWM2OD1zLkezOFY3KM7:TR?=NEn0R2pUSU6JRWK=
TE-5MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\hWmlEPTB;MT63PVE{QSEQvF2=NEPZUXZUSU6JRWK=
CANMmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzBOGd5UUN3ME2xMlgzOjV{IN88US=>MVLTRW5ITVJ?
SK-UT-1MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTJwMU[2PVMh|ryPM2\sV3NCVkeHUh?=
JVM-2NFr6S5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHKXpFWUUN3ME2yMlM3Ojh2IN88US=>M3H5bnNCVkeHUh?=
LB771-HNCM3TIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XnRmlEPTB;Mj61O|U2OSEQvF2=Mk\WV2FPT0WU
NCCITMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2[5d2lEPTB;Mj64OlYyPiEQvF2=NHS3OmlUSU6JRWK=
NCI-H2126NXfWTJI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\kfGlEPTB;Mj64O|U2OiEQvF2=NIXhNYtUSU6JRWK=
Calu-6NFfQTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XO[WlEPTB;Mz6wOVc1OSEQvF2=MV\TRW5ITVJ?
SK-LMS-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\CTWM2OD1|LkGxPFg3KM7:TR?=NGnDS4RUSU6JRWK=
ARH-77NGfhc|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVz1e|lNUUN3ME2zMlQ3QTF3IN88US=>NWDkdFlEW0GQR1XS
NB17NHXKO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXXpSGQ{UUN3ME2zMlY{QDR5IN88US=>NGTMUYhUSU6JRWK=
A253MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTNwN{OyOFYh|ryPMYfTRW5ITVJ?
OPM-2Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfM[mRpUUN3ME20MlI4Pjh3IN88US=>M4[yNHNCVkeHUh?=
MV-4-11NXrUS4lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPXTWM2OD12LkO2OFU1KM7:TR?=NFTGcI9USU6JRWK=
SRM{W5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rwUGlEPTB;ND60PVk2PCEQvF2=M{nWb3NCVkeHUh?=
KG-1M3vkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDndnpKSzVyPUSuOlA5PDVizszNMmCyV2FPT0WU
OCI-AML2M1;N[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XEbWlEPTB;NT64OlE2PCEQvF2=Mlf0V2FPT0WU
D-247MGNUnQW5lsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojmTWM2OD14LkGyOVE6KM7:TR?=MUfTRW5ITVJ?
DJM-1M1PIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTZwNEi1OVgh|ryPNFjIRZhUSU6JRWK=
RPMI-6666MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7pTWM2OD15LkK3NFY4KM7:TR?=NWnmZ2tjW0GQR1XS
KARPAS-45NYXVNotUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXYNW9KSzVyPUeuOVE3PzFizszNM2LmeHNCVkeHUh?=
LP-1NImzN5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{X2XGlEPTB;Nz61OFc5OiEQvF2=NHnGT3ZUSU6JRWK=
RS4-11MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3j6c2lEPTB;Nz62OVc5PyEQvF2=Mn3sV2FPT0WU
DU-4475MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfGe48xUUN3ME24MlIyPjV{IN88US=>NGfYZ2FUSU6JRWK=
MONO-MAC-6NEHXW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYCxW5ZtUUN3ME24MlI4ODZ4IN88US=>M2jJ[HNCVkeHUh?=
NCI-SNU-16MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jMWmlEPTB;OD61OlEzQCEQvF2=MnL0V2FPT0WU
SJSA-1NHnFN|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRThwN{K4NFUh|ryPNUnKXFVQW0GQR1XS
MMAC-SFMmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRThwN{mzNFch|ryPNGXEO3hUSU6JRWK=
SK-NEP-1M1LzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRThwOEmxOVUh|ryPMW\TRW5ITVJ?
J-RT3-T3-5NFq2WpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRThwOU[1Nlkh|ryPM4XBSnNCVkeHUh?=
SKM-1M{\OPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnztTWM2OD17LkCxO|M1KM7:TR?=M3zHWXNCVkeHUh?=
LB2241-RCCMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXTWmRKSzVyPUmuNFIxOTJizszNMm[0V2FPT0WU
SIG-M5MmnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITHTXFKSzVyPUmuNFI1QTNizszNMXPTRW5ITVJ?
EVSA-TM3nxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;sTWM2OD17LkK3O|k{KM7:TR?=NEfrOHVUSU6JRWK=
GT3TKBNFPaW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLGTWM2OD17LkO1OVQ3KM7:TR?=NFT2[XRUSU6JRWK=
NB6NV;JbnVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;XTWM2OD17LkmyNlU6KM7:TR?=M2HGeXNCVkeHUh?=
EHEBNED2VnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoCyTWM2OD1zMD6wOlU3KM7:TR?=M1i2NXNCVkeHUh?=
HELNGnaNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DiZmlEPTB;MUCuOFc4PiEQvF2=NW\VW|QxW0GQR1XS
ALL-POMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkOxTWM2OD1zMD63PVM5KM7:TR?=MnXjV2FPT0WU
TGWM3XNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrETWM2OD1zMT6yPFI5KM7:TR?=MlvsV2FPT0WU
BC-3NWXCTYtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInINpZKSzVyPUGyMlEyOzhizszNMYXTRW5ITVJ?
IA-LMNX6wNnAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nLWmlEPTB;MUKuOFQ1PSEQvF2=M{TBenNCVkeHUh?=
UACC-257M2\1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTF{LkmxPVgh|ryPM1XUPXNCVkeHUh?=
KP-N-YSM3zVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHITWM2OD1zMj65Nlg{KM7:TR?=NGDZPJpUSU6JRWK=
RajiMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;RTWM2OD1zMz63OFk4KM7:TR?=NYHSXFBEW0GQR1XS
SF539NX[xepd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTF|Lki1OVch|ryPNEPIPHFUSU6JRWK=
DMS-153NVHpTWxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2OwSWlEPTB;MUSuNFAzQCEQvF2=M4j0N3NCVkeHUh?=
L-540M2\5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7yTWM2OD1zNT6wOlczKM7:TR?=M2DQUHNCVkeHUh?=
MN-60M1G2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTF3LkG5O|kh|ryPNFKxe3NUSU6JRWK=
RPMI-8866MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTF5LkS0OVQh|ryPM4i1PHNCVkeHUh?=
NCI-H510ANVflT|ZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTF7LkO5O|Mh|ryPM3nle3NCVkeHUh?=
NB13NGfUVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfHTWM2OD1zOT60PFc4KM7:TR?=Mlf4V2FPT0WU
HAL-01MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPYTWM2OD1zOT63OVQ{KM7:TR?=NHftNIJUSU6JRWK=
NCI-H720NWHaSJNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TDbWlEPTB;MkCuNlc{OyEQvF2=MX7TRW5ITVJ?
REHMmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrESmlKSzVyPUKwMlY{PTdizszNM4\OSnNCVkeHUh?=
KNS-81-FDM3;jR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXexWndGUUN3ME2yN{4yPDZizszNM1nDNnNCVkeHUh?=
HC-1NFfaeWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\lS5ppUUN3ME2yOE42PTVzIN88US=>M{PrdnNCVkeHUh?=
NCI-H2141M4DIbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;vbolxUUN3ME2yOE44PzV2IN88US=>M{XMbXNCVkeHUh?=
MOLT-4NE\BUFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFO0bJNKSzVyPUK2MlY4PTNizszNNVGwbpRrW0GQR1XS
OMC-1M4np[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnlPZIxUUN3ME2yO{4yPDJ{IN88US=>NXPob2FOW0GQR1XS
LC-1FMnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvUNXY3UUN3ME2yO{4{OjR3IN88US=>NYGyTXNGW0GQR1XS
NCI-H1304MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnud4RMUUN3ME2yPE4yPjJ6IN88US=>NVPMWHI5W0GQR1XS
BC-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnweGNKSzVyPUK4MlY2OSEQvF2=NHLE[YZUSU6JRWK=
NCI-H64MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;xS4ZKSzVyPUK5MlYzPTNizszNNFjycFBUSU6JRWK=
MOLT-16MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXn3OWNSUUN3ME2yPU43Ojl{IN88US=>MYDTRW5ITVJ?
U-87-MGNXHWRZBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYf3b3FjUUN3ME2zNE44PjZizszNNWTZNIpLW0GQR1XS
GAKNY\yWJU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHm4TGhKSzVyPUOxMlI3QDZizszNNFnTdIZUSU6JRWK=
ES8NGDSW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXITWM2OD1|Mj6xNlUzKM7:TR?=NVf0[G1LW0GQR1XS
HCC1599M1fG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTN{LkOzNlUh|ryPMl7tV2FPT0WU
EB-3NF[0VlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnxWYh1UUN3ME2zOE4{OTF5IN88US=>MXzTRW5ITVJ?
HCC1187NIDZenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWnmUXBNUUN3ME2zOU45ODV{IN88US=>M36zUHNCVkeHUh?=
SK-PN-DWM2PuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHnBUlRKSzVyPUO2MlE6PDNizszNMorGV2FPT0WU
JVM-3NVHJSnpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLQXVRKSzVyPUO3MlI{OzhizszNNEjzSXZUSU6JRWK=
HCC2157NVG4W21PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DpOmlEPTB;M{euPVk1PiEQvF2=NYDFeY46W0GQR1XS
A4-FukM3uxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2flW2lEPTB;M{iuNVAxQSEQvF2=M33YNnNCVkeHUh?=
COR-L279MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXoTWM2OD12MD6yPFUyKM7:TR?=NYfq[IJxW0GQR1XS
DELMnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTGTWM2OD12MT65NFg3KM7:TR?=MWHTRW5ITVJ?
NCI-H1395NHzpeW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTR{LkCxOlMh|ryPMV\TRW5ITVJ?
MHH-NB-11MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTR|LkC4NVgh|ryPMW\TRW5ITVJ?
NCI-H2107MnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\zZnpKSzVyPUSzMlQ5PDZizszNMnzsV2FPT0WU
NEC8MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mln3TWM2OD12ND6zN|Yh|ryPM{jMNnNCVkeHUh?=
COLO-684MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DMVGlEPTB;NE[uNlI2QCEQvF2=M33LPHNCVkeHUh?=
LS-411NMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTR6LkS3OFgh|ryPNHH4VWdUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Kinase autophosphorylation assays Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.

Cell Assay:

[1]

Cell lines Ba/F3 cell lines
Concentrations ~32 nM
Incubation Time 72 hours
Method

Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.

Animal Study:

[3]

Animal Models EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
Formulation DMSO
Dosages 30 mg/kg
Administration Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] O'Hare T, et al. Cancer Res. 2005, 65(11), 4500-4505.

[2] Shah NP, et al. Blood, 2006, 108(1), 286-291.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02709083 Not yet recruiting Chronic Myelogenous Leukemia|Chronic Myeloid Leukemia|Leukemia Emory University December 2016 Phase 2
NCT02815059 Not yet recruiting Acute Lymphoblastic Leukemia University of Utah|Janssen, LP August 2016 Phase 1
NCT02819804 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblast  ...more B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|Refractory Childhood Acute Lymphoblastic Leukemia Northwestern University|National Cancer Institute (NCI) July 2016 Phase 1
NCT02848131 Recruiting Chronic Kidney Disease Mayo Clinic July 2016 Phase 2
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto June 2016 Phase 2

view more

Chemical Information

Download Dasatinib SDF
Molecular Weight (MW) 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms BMS-354825
Solubility (25°C) * In vitro DMSO 98 mg/mL (200.81 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Src Products

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Bosutinib (SKI-606)

    Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.

  • KX2-391

    KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.

  • PP1

    PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • PP2

    PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

  • WH-4-023

    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Recently Viewed Items

Tags: buy Dasatinib | Dasatinib ic50 | Dasatinib price | Dasatinib cost | Dasatinib solubility dmso | Dasatinib purchase | Dasatinib manufacturer | Dasatinib research buy | Dasatinib order | Dasatinib mouse | Dasatinib chemical structure | Dasatinib mw | Dasatinib molecular weight | Dasatinib datasheet | Dasatinib supplier | Dasatinib in vitro | Dasatinib cell line | Dasatinib concentration | Dasatinib nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us